STERIS (NYSE:STE) VP John Adam Zangerle Sells 1,419 Shares

June 17, 2026 by InsiderTrades.com

Key Points

STERIS VP John Adam Zangerle sold 1,419 shares on June 15 at an average price of $209.28, a transaction worth about $296,968. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still owns 35,259 shares.
STERIS posted mixed quarterly results, with earnings per share of $2.83 missing analysts’ estimate of $2.86, while revenue of $1.59 billion matched expectations. Revenue rose 6.7% year over year, and the company reaffirmed FY 2027 EPS guidance of 11.10 to 11.30.
The company also announced a quarterly dividend of $0.63 per share, payable June 26, implying an annualized dividend of $2.52 and a yield of 1.2%. Analysts currently rate the stock a “Moderate Buy” with a consensus price target of $278.

STERIS plc (NYSE:STE - Get Free Report) VP John Adam Zangerle sold 1,419 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the transaction, the vice president owned 35,259 shares of the company's stock, valued at approximately $7,379,003.52. This represents a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Trading Up 0.3%

Shares of STE stock opened at $206.64 on Wednesday. STERIS plc has a 52-week low of $195.14 and a 52-week high of $269.44. The stock has a market cap of $20.14 billion, a price-to-earnings ratio of 26.06 and a beta of 0.93. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The firm has a fifty day moving average of $215.59 and a 200-day moving average of $236.34.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the company posted $2.74 EPS. The company's quarterly revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, equities research analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a $0.63 dividend. The ex-dividend date is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS's dividend payout ratio is currently 31.78%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. KeyCorp dropped their price objective on shares of STERIS from $291.00 to $269.00 and set an "overweight" rating for the company in a research note on Wednesday, May 13th. Wall Street Zen cut shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 6th. Weiss Ratings cut shares of STERIS from a "hold (c+)" rating to a "hold (c)" rating in a research note on Wednesday, May 27th. Finally, Piper Sandler restated an "overweight" rating and issued a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $278.00.

View Our Latest Stock Analysis on STE

Institutional Investors Weigh In On STERIS

A number of hedge funds have recently made changes to their positions in the company. Trust Co. of Vermont increased its position in shares of STERIS by 30.2% during the 4th quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 38 shares in the last quarter. Bailard Inc. increased its position in shares of STERIS by 3.5% during the 4th quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider's stock worth $283,000 after purchasing an additional 38 shares in the last quarter. Magnolia Capital Advisors LLC increased its position in shares of STERIS by 1.2% during the 3rd quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider's stock worth $888,000 after purchasing an additional 41 shares in the last quarter. Colonial Trust Co SC increased its position in shares of STERIS by 0.3% during the 3rd quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider's stock worth $3,051,000 after purchasing an additional 42 shares in the last quarter. Finally, Geneos Wealth Management Inc. increased its position in shares of STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 45 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.

About STERIS

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.